Compare DigitalOcean Holdings Inc (DOCN) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DigitalOcean Holdings Inc vs Novo Nordisk A/S — how do they compare? DigitalOcean Holdings Inc trades at $126.43 (market cap $14.57B), while Novo Nordisk A/S trades at $38.16 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 11.3× DigitalOcean Holdings Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while DigitalOcean Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold DigitalOcean Holdings Inc for 43 Days and Novo Nordisk A/S for 116 Days on average.
| DOCN | NVO | |
|---|---|---|
Market Cap | $14.57B | $165.31B |
Volume | 2,261,786 | 11,432,838 |
Sector | Technology | Health |
52-Week High | $181.29 | $63.98 |
52-Week Low | $37.30 | $35.29 |
Typical Hold Time | 43 Days | 116 Days |
Enterprise Value | $15.33B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DigitalOcean trades at $127.28, down 2.89% today, with strong technical support at $126 and resistance at $130. The company shows robust revenue growth from $576M in 2022 to $901M in 2025, with net income turning positive to $259M. Recent AI-focused product launches including Agent Droplets and Managed Agents position the company for continued growth in cloud services.
Despite high valuation multiples (P/E 57.85, P/S 14.34), analyst consensus remains bullish with a $172.73 price target representing 36% upside. Key risks include capital intensity from expansion and high debt levels, while institutional accumulation and consistent earnings beats support the growth narrative.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.96 surpassing the $0.82 estimate. The company maintains robust cash flow generation with $119.1B operating cash flow in 2025.
NVO presents compelling value with a 9.71 P/E ratio below industry averages and 59% analyst buy ratings. Upside potential exists to the $44.67 consensus target, though competition from Eli Lilly and FDA regulatory delays pose near-term risks. The obesity drug pipeline remains a key growth driver, supported by recent licensing deals totaling nearly $4B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
